Article Text

Download PDFPDF
Point: patients with native aortic regurgitation can be treated with transcatheter aortic valve implantation
  1. Sahoor A Khan,
  2. Suzanne J Baron
  1. Division of Cardiology, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA
  1. Correspondence to Dr Suzanne J Baron, Lahey Hospital and Medical Center, Burlington, MA 01805-0001, USA; suzanne.j.baron{at}


Approximately 2% of people between the ages of 70 and 83 suffer from moderate or greater aortic regurgitation (AR) in the United States. Left untreated, this disease is progressive and fatal; however, up to 8% of patients with AR, who meet the criteria for surgical intervention, do not receive treatment. As such, there is a pressing need to address the lack of treatment options for the thousands of patients with AR who meet a class I indication for aortic valve replacement but who still do not receive surgery. The advent of transcatheter aortic valve implantation (TAVI) has significantly altered the paradigm of treatment for valvular heart disease and is now a well-established therapeutic option for patients with severe aortic stenosis. While transcatheter devices dedicated for the treatment of AR are under investigation, they are not commercially available at this time. Nevertheless, there is a growing body of data that demonstrate acceptable safety and efficacy for the off-label use of current TAVI devices for the treatment of severe AR. Given the dearth of treatment options for inoperable patients with severe AR, available TAVI devices should be considered for this patient population.

  • aortic regurgitation
  • transcatheter aortic valve replacement

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @suzannejbaron

  • Contributors Both authors have contributed substantially to this article.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests SJB reports the following conflicts of interest over the past 12 months: consulting/advisory board income: Boston Scientific Corporation, Abiomed, Abbott, Edwards Lifesciences and Mitra Labs; and research support: Abiomed.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles